Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Absenteeism and business costs: does substance abuse matter?

Foster WH, Vaughan RD.

J Subst Abuse Treat. 2005 Jan;28(1):27-33.

PMID:
15723729
2.

Organizational and client determinants of cost in outpatient substance abuse treatment.

Beaston-Blaakman A, Shepard D, Horgan C, Ritter G.

J Ment Health Policy Econ. 2007 Mar;10(1):3-13.

PMID:
17417043
3.

Treatment for substance use disorders in a privately insured population under managed care: costs and services use.

Greenfield SF, Azzone V, Huskamp H, Cuffel B, Croghan T, Goldman W, Frank RG.

J Subst Abuse Treat. 2004 Dec;27(4):265-75.

PMID:
15610828
4.

Income and employment of people living with combined HIV/AIDS, chronic mental illness, and substance abuse disorders.

Conover CJ, Arno P, Weaver M, Ang A, Ettner SL.

J Ment Health Policy Econ. 2006 Jun;9(2):71-86.

PMID:
17007485
5.

The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.

Ivanova JI, Birnbaum HG, Samuels S, Davis M, Phillips AL, Meletiche D.

Pharmacoeconomics. 2009;27(8):681-91. doi: 10.2165/11314700-000000000-00000.

PMID:
19712010
6.

Substance abuse and the uninsured worker in the United States.

Galvin DM, Miller TR, Spicer RS, Waehrer GM.

J Public Health Policy. 2007;28(1):102-17.

PMID:
17363941
7.
8.

The economic impact of bipolar disorder in an employed population from an employer perspective.

Gardner HH, Kleinman NL, Brook RA, Rajagopalan K, Brizee TJ, Smeeding JE.

J Clin Psychiatry. 2006 Aug;67(8):1209-18.

PMID:
16965198
9.

Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.

Weaver MR, Conover CJ, Proescholdbell RJ, Arno PS, Ang A, Uldall KK, Ettner SL.

J Ment Health Policy Econ. 2009 Mar;12(1):33-46.

PMID:
19346565
10.

Effectiveness and benefit-cost of peer-based workplace substance abuse prevention coupled with random testing.

Miller TR, Zaloshnja E, Spicer RS.

Accid Anal Prev. 2007 May;39(3):565-73. Epub 2006 Nov 27.

PMID:
17125723
11.

The economic costs of illicit drug use in Ontario, 1992.

Xie X, Rehrn J, Single E, Robson L, Paul J.

Health Econ. 1998 Feb;7(1):81-5.

PMID:
9541086
12.

Workplace drug abuse policy.

McGuire TG, Ruhm CJ.

J Health Econ. 1993 Apr;12(1):19-38.

PMID:
10171449
13.

Financial viability of screening for drugs of abuse.

Peat MA.

Clin Chem. 1995 May;41(5):805-8. Review.

14.

Economic costs of drug abuse: financial, cost of illness, and services.

Cartwright WS.

J Subst Abuse Treat. 2008 Mar;34(2):224-33. Epub 2007 Jun 27. Review.

PMID:
17596904
15.

Pain exacerbation as a major source of lost productive time in US workers with arthritis.

Ricci JA, Stewart WF, Chee E, Leotta C, Foley K, Hochberg MC.

Arthritis Rheum. 2005 Oct 15;53(5):673-81.

16.

Drug use, drug abuse, and labour market outcomes.

Buchmueller TC, Zuvekas SH.

Health Econ. 1998 May;7(3):229-45.

PMID:
9639336
17.

Fostering a drug-free workplace.

Montoya ID, Elwood WN.

Health Care Superv. 1995 Sep;14(1):1-13.

PMID:
10172396
18.

Economic costs of benign prostatic hyperplasia in the private sector.

Saigal CS, Joyce G.

J Urol. 2005 Apr;173(4):1309-13.

PMID:
15758787
19.

Substance abuse in the workplace: epidemiology, effects, and industry response.

Bush DM, Autry JH 3rd.

Occup Med. 2002 Jan-Mar;17(1):13-25, iii. Review.

PMID:
11726333
20.

Solutions to workplace substance abuse: prevention and treatment strategies.

Apgar KR.

Issue Brief (Inst Health Care Costs Solut). 2003 Jan-Feb;2(1):1-16. No abstract available.

PMID:
12825604

Supplemental Content

Support Center